Macrolides for asthma: A systematic review and meta-analysis of randomized trials. Ologundudu LM, Wong MM, Islam N, Rayner DG, Chu AWL, Loeb M, Rivera-Spoljaric K, Chipps B, Sumino K, Oppenheimer J, Nyenhuis SM, Israel E, Hoyte F, Perry TT, McCabe E, Press VG, Rangel S, Guyatt GH, Shade LE, O'Byrne PM, Orr H, Sue-Wah-Sing D, Melendez A, Winders T, Gardner DD, Przywara K, Mosnaim G, Bacharier LB, Rank MA, Chu DK. J Allergy Clin Immunol. 2026 Feb 5:S0091-6749(26)00078-3. doi: 10.1016/j.jaci.2026.01.024. Epub ahead of print. PMID: 41654262.
Conclusions: Macrolides likely reduce severe exacerbations and improve asthma control and quality of life with little to no difference in serious harms among patients with type 2 high inflammation or type 2 low inflammation asthma
Débits inspiratoires nécessaire par dispositif, Inhalopedia, IUCPQ
BCGuidelines.ca, Appendix C: Asthma medication table
RxFiles, COPD, NEW DRUGS, NEW DEVICES AND CONSIDERATIONS FOR BEST PRACTICE, September 2015
CONCLUSIONS: In patients with mild asthma, as-needed budesonide-formoterol provided superior asthma-symptom control to as-needed terbutaline, assessed according to electronically recorded weeks with well-controlled asthma, but was inferior to budesonide maintenance therapy. Exacerbation rates with the two budesonide-containing regimens were similar and were lower than the rate with terbutaline. Budesonide-formoterol used as needed resulted in substantially lower glucocorticoid exposure than budesonide maintenance therapy.